Pulmatrix Advances Merger with Cullgen, Seeks Regulatory Approval for Strategic Growth

Pulmatrix Pursues Merger Approval Amid Ongoing Strategic Developments

Pulmatrix, Inc. is currently advancing its merger efforts with Cullgen Inc., focusing on obtaining the necessary approval from the China Securities Regulatory Commission (CSRC). This strategic move is critical for Pulmatrix as it seeks to integrate Cullgen's capabilities into its operations, thereby enhancing its portfolio of inhaled therapeutic products aimed at treating migraine and respiratory diseases. The merger agreement, first signed in November 2024, has undergone amendments, including a recent waiver of the "No Solicitation" clause, allowing both companies to explore alternative transactions while they await regulatory green lights. Interim CEO Peter Ludlum underscores the significance of this merger, emphasizing that despite the effective Form S-4 filing in May 2025 and shareholder approval in June 2025, the CSRC's decision remains a pivotal hurdle.

The completion of this merger is contingent not only on CSRC approval but also on Nasdaq's authorization for the listing of Pulmatrix common stock shares to be issued as part of the merger. This multi-faceted approval process illustrates the complexities involved in cross-border mergers, particularly in the biopharmaceutical sector, where regulatory scrutiny is rigorous. If the merger is finalized, it will allow Pulmatrix to continue Cullgen's operations under a unified corporate structure, potentially accelerating the development of novel therapies that address significant unmet medical needs in their target markets.

As of September 30, 2025, Pulmatrix’s financial health appears stable, reporting cash and cash equivalents of $4.8 million, which is projected to sustain operations through at least the fourth quarter of 2026. This financial outlook is bolstered by the company's operational efficiencies, which are crucial as it navigates the merger process. The ongoing discussions surrounding the merger reflect Pulmatrix's commitment to enhancing its competitive position and optimizing its product development strategies, particularly through its proprietary iSPERSE™ technology.

In addition to its merger pursuits, Pulmatrix remains focused on its core mission of developing innovative inhaled therapies. The company actively engages in refining its product pipeline to address the urgent needs of patients dealing with migraine and respiratory conditions. As Pulmatrix navigates this critical juncture, its strategies indicate a forward-thinking approach aimed at maximizing its impact in the biopharmaceutical landscape.